Promatix Biosciences has been awarded non-dilutive funding through the Innovate UK Biomedical Catalyst program to support development of its first-in-class EGFR-EphA2 cis-bispecific antibody-drug conjugate, or ADC. The announcement positions the grant as a key step in moving the company’s lead program forward.
Innovate UK’s Biomedical Catalyst is aimed at helping promising biomedical projects progress, and the non-dilutive structure means the support does not require the company to give up equity. For Promatix, the award provides external backing for continued work on a drug candidate built around dual targeting of EGFR and EphA2.
The program is described as a cis-bispecific ADC, a format that combines a bispecific targeting strategy with an antibody-drug conjugate approach. While the company did not outline full development details in the trimmed release, the grant underscores interest in next-generation ADC designs that seek to improve how therapies are directed toward disease-related targets.
With the new Innovate UK funding in place, Promatix is set to advance the EGFR-EphA2 ADC program through its next research and development stages. The award also adds visibility to the company’s work in the competitive ADC field, where novel targeting formats continue to draw attention from researchers, investors and public funding bodies.
